Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study

被引:86
作者
Vredenburgh, James J. [1 ]
Cloughesy, Timothy [2 ]
Samant, Meghna [3 ]
Prados, Michael [4 ]
Wen, Patrick Y. [5 ]
Mikkelsen, Tom [6 ]
Schiff, David [7 ]
Abrey, Lauren E. [8 ]
Yung, W. K. Alfred [9 ]
Paleologos, Nina [10 ]
Nicholas, Martin K. [11 ]
Jensen, Randy [12 ]
Das, Asha [3 ]
Friedman, Henry S.
机构
[1] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Genentech Inc, San Francisco, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
[7] Univ Virginia, Charlottesville, VA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[9] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] NorthShore Univ HealthSyst, Evanston, IL USA
[11] Univ Chicago, Chicago, IL 60637 USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
关键词
Corticosteroid; Glioblastoma; Anti-VEGF; Antiangiogenic; PHASE-II TRIAL; PLUS IRINOTECAN; RECURRENT GLIOBLASTOMA; MALIGNANT GLIOMA; EFFICACY; PATTERNS; TUMORS;
D O I
10.1634/theoncologist.2010-0105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Vascular endothelial growth factor inhibitors have corticosteroid-sparing effects in patients with high-grade gliomas. We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009; 27: 4733-4740). Methods. BRAIN was a phase II, multicenter, randomized, noncomparative trial of BEV alone (n = 85) or in combination with irinotecan (CPT-11) (n = 82) in adults with recurrent glioblastoma. Median corticosteroid dose for patients who used corticosteroids at baseline was summarized by treatment arm; the percentage of patients who had sustained (>= 50% corticosteroid dose reduction for >= 50% of time on study drug) or complete (discontinuation of corticosteroid for >= 25% of time on study drug) reduction in corticosteroid dose overall and by objective response and progression-free survival was calculated. The incidence of corticosteroidrelated adverse events was summarized. Results. In each treatment group, 50% of patients were using systemic corticosteroids at baseline. The majority of those experienced a reduction in dose while receiving BEV-based therapy. Thirteen (30.2%) BEV and 20 (46.5%) BEV + CPT-11 patients had a sustained reduction of corticosteroid dose; 7 (16.3%) BEV and 9 20.9%) BEV + CPT-11 patients had a complete reduction of corticosteroid dose. The majority of patients who had an objective response or progression-free survival >6 months experienced corticosteroid dose reduction. Approximately 64% of patients who used corticosteroids while receiving BEV-based therapy experienced infection. Conclusion. BEV may have corticosteroid-sparing effects in patients with recurrent glioblastoma. Corticosteroid reduction may positively affect patient health-related quality of life. Given the exploratory nature of the analyses in a noncomparative study, these results should be interpreted cautiously. The Oncologist 2010;15:1329-1334
引用
收藏
页码:1329 / 1334
页数:6
相关论文
共 14 条
[1]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[2]   Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: A novel glucocorticoid hierarchy [J].
Buttgereit, F ;
Brand, MD ;
Burmester, GR .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (02) :363-368
[3]   Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].
Friedman, Henry S. ;
Prados, Michael D. ;
Wen, Patrick Y. ;
Mikkelsen, Tom ;
Schiff, David ;
Abrey, Lauren E. ;
Yung, W. K. Alfred ;
Paleologos, Nina ;
Nicholas, Martin K. ;
Jensen, Randy ;
Vredenburgh, James ;
Huang, Jane ;
Zheng, Maoxia ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740
[4]  
*GEN INC, 2009, AV PACK INS 7 09, P12020
[5]   USE OF CORTICOSTEROIDS IN NEUROONCOLOGY [J].
KOEHLER, PJ .
ANTI-CANCER DRUGS, 1995, 6 (01) :19-33
[6]   Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].
Kreisl, Teri N. ;
Kim, Lyndon ;
Moore, Kraig ;
Duic, Paul ;
Royce, Cheryl ;
Stroud, Irene ;
Garren, Nancy ;
Mackey, Megan ;
Butman, John A. ;
Camphausen, Kevin ;
Park, John ;
Albert, Paul S. ;
Fine, Howard A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745
[7]   RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].
MACDONALD, DR ;
CASCINO, TL ;
SCHOLD, SC ;
CAIRNCROSS, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280
[8]   Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence [J].
Norden, A. D. ;
Young, G. S. ;
Setayesh, K. ;
Muzikansky, A. ;
Klufas, R. ;
Ross, G. L. ;
Ciampa, A. S. ;
Ebbeling, L. G. ;
Levy, B. ;
Drappatz, J. ;
Kesari, S. ;
Wen, P. Y. .
NEUROLOGY, 2008, 70 (10) :779-787
[9]  
Posner, 2009, NEUROLOGICAL COMPLIC
[10]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205